M&A Deal Summary |
|
|---|---|
| Date | 2018-11-07 |
| Target | IRX Therapeutics |
| Sector | Life Science |
| Buyer(s) | Ernexa Therapeutics |
| Deal Type | Add-on Acquisition |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2018 |
| Sector | Life Science |
Ernexa Therapeutics is focused on providing cytokine-based therapy to treat patients with cancer, both as a single agent and in combination with other anti-cancer therapies. Its most advanced program is studying the safety and efficacy of IRX-2 in patients with head and neck cancer. Ernexa Therapeutics was founded in 2018 and is based in Cambridge, Massachusetts.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 3 |
| Sector: Life Science M&A | 1 of 2 |
| Type: Add-on Acquisition M&A Deals | 1 of 1 |
| State: New York M&A | 1 of 1 |
| Country: United States M&A | 1 of 3 |
| Year: 2018 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-08-13 |
Buzztime
Carlsbad, California, United States Buzztime delivers interactive entertainment and innovative technology that helps its customers acquire, engage, and retain their patrons. The company's tablets, mobile app, and technology offer engaging solutions to establishments that have guests who experience dwell time, such as in bars, restaurants, casinos, and senior living centers. Buzztime was founded in 1983 and is based in Carlsbad, California. |
Buy | - |